Active	Status	Sponsor type	Region	Phase	Filter
7 Active 0 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

7 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Oehlwein, Christian
ADOPTION, NCT04990284 / 2020-002754-24: eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.	Completed	4	106	Europe	Opicapone, BIA 9-1067, L-DOPA/DDCI, Levodopa	Bial - Portela C S.A., Bial - Portela & Ca, S.A.	Parkinson Disease	04/23	04/23
TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations	Completed	3	507	Europe, Canada, US, RoW	Tavapadon, PF-06649751, CVL-751, Placebo	AbbVie	Parkinson Disease	01/24	02/24
TEMPO-2, NCT04223193 / 2019-002950-22: Flexible-Dose Trial in Early Parkinson's Disease (PD)	Completed	3	304	Europe, US, RoW	Tavapadon, PF-06649751, CVL-751, Placebo	Cerevel Therapeutics, LLC	Parkinson Disease	10/24	10/24
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy	Recruiting	3	102	Europe, Canada, US, RoW	Ampreloxetine, TD-9855, Placebo	Theravance Biopharma	Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy	12/24	01/27
Stefani, Alessandro
TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations	Completed	3	507	Europe, Canada, US, RoW	Tavapadon, PF-06649751, CVL-751, Placebo	AbbVie	Parkinson Disease	01/24	02/24
TEMPO-2, NCT04223193 / 2019-002950-22: Flexible-Dose Trial in Early Parkinson's Disease (PD)	Completed	3	304	Europe, US, RoW	Tavapadon, PF-06649751, CVL-751, Placebo	Cerevel Therapeutics, LLC	Parkinson Disease	10/24	10/24
Mel-Immuno-Reu, NCT06780397: Clinical and Ultrasound Incidence of Rheumatologic Immune Related Adverse Events in Stage IIB-IV Melanoma Patients	Not yet recruiting	N/A	100	Europe	Joint ultrasonography, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 version 3.0	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	Melanoma, Stage II, Melanoma Stage III, Melanoma Stage IV	02/27	02/28

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Oehlwein, Christian
ADOPTION, NCT04990284 / 2020-002754-24: eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.	Completed	4	106	Europe	Opicapone, BIA 9-1067, L-DOPA/DDCI, Levodopa	Bial - Portela C S.A., Bial - Portela & Ca, S.A.	Parkinson Disease	04/23	04/23
TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations	Completed	3	507	Europe, Canada, US, RoW	Tavapadon, PF-06649751, CVL-751, Placebo	AbbVie	Parkinson Disease	01/24	02/24
TEMPO-2, NCT04223193 / 2019-002950-22: Flexible-Dose Trial in Early Parkinson's Disease (PD)	Completed	3	304	Europe, US, RoW	Tavapadon, PF-06649751, CVL-751, Placebo	Cerevel Therapeutics, LLC	Parkinson Disease	10/24	10/24
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy	Recruiting	3	102	Europe, Canada, US, RoW	Ampreloxetine, TD-9855, Placebo	Theravance Biopharma	Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy	12/24	01/27
Stefani, Alessandro
TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations	Completed	3	507	Europe, Canada, US, RoW	Tavapadon, PF-06649751, CVL-751, Placebo	AbbVie	Parkinson Disease	01/24	02/24
TEMPO-2, NCT04223193 / 2019-002950-22: Flexible-Dose Trial in Early Parkinson's Disease (PD)	Completed	3	304	Europe, US, RoW	Tavapadon, PF-06649751, CVL-751, Placebo	Cerevel Therapeutics, LLC	Parkinson Disease	10/24	10/24
Mel-Immuno-Reu, NCT06780397: Clinical and Ultrasound Incidence of Rheumatologic Immune Related Adverse Events in Stage IIB-IV Melanoma Patients	Not yet recruiting	N/A	100	Europe	Joint ultrasonography, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 version 3.0	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	Melanoma, Stage II, Melanoma Stage III, Melanoma Stage IV	02/27	02/28